Ash 2022 preview – Affimed and Aptose score
In oncology settings outside multiple myeloma investors have picked two early winners.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
EHA 2021 movers – more fallers than risers
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 – UK biotech's hollow victory
Results with Loxo-305 could justify Lilly’s acquisition of Loxo, but its inventor, the UK’s Redx, can just read ‘em and weep.
Ash 2019 winners and losers
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
EHA 2019 – Sunesis chases Arqule, but remissions prove elusive
Sunesis’s vecabrutinib has yet to put a patient into remission, so hope rests on higher dosing of this next-generation BTK inhibitor.
